Frist Affiliated Hospital of Kunming Medical University
Welcome,         Profile    Billing    Logout  
 8 Trials 
31 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yang, Bin
NCT05312268: Rasburicase Treatment in Chronic Gouty Arthritis

Recruiting
4
60
RoW
Rasburicase
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Chronic Gout
10/24
04/25
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed
3
336
Canada, RoW
Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2
Reistone Biopharma Company Limited
Atopic Dermatitis
08/22
05/23
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting
3
330
RoW
SHR0302, Placebo
Reistone Biopharma Company Limited
Alopecia Areata
10/23
02/24
NCT06281561: Dexmedetomidine Premedication for Post-anaesthesia Sleep Disturbance

Not yet recruiting
3
110
NA
Normal Saline, Dexmedetomidine
The First Affiliated Hospital of Xiamen University
Postoperative Sleep Disturbance
11/24
12/24
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Not yet recruiting
3
500
RoW
TQH2722 injection, Placebo of TQH2722 injection
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Atopic Dermatitis
10/25
06/26
NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting
2/3
645
RoW
SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo
Reistone Biopharma Company Limited
Atopic Dermatitis
09/23
07/24
BK2016.01, NCT03146637: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Recruiting
2
80
RoW
Activated CIK, CIK
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital
Advanced Liver Cancer
01/21
01/21
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Hourglass Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC
Recruiting
2
28
RoW
Camrelizumab, SHR-1210, Famitinib, SHR-1020
Qian Chu, Jiangsu HengRui Medicine Co., Ltd.
Sarcomatoid Carcinoma of Lung
12/24
06/25
SSGJ-611-AD-II-01, NCT05544591: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Completed
2
93
RoW
611 Q2W, 611 Q4W, Matching placebo, placebo
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Dermatitis, Atopic
07/23
09/23
NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Recruiting
2
200
RoW
LP-003, Placebo, Omalizumab
Longbio Pharma
Chronic Spontaneous Urticaria
01/25
01/25
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting
2
160
RoW
TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Atopic Dermatitis
03/24
03/24
AtDvance, NCT06447506: Long-Term Study () to Evaluate GSK1070806 in Atopic Dermatitis.

Recruiting
2
159
Europe, Canada, Japan, US, RoW
GSK1070806
GlaxoSmithKline
Dermatitis, Atopic
11/29
11/29
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Recruiting
2
175
Europe, Canada, Japan, US, RoW
GSK1070806, Placebo
GlaxoSmithKline
Dermatitis, Atopic
08/24
06/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT05713110: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Recruiting
2
140
RoW
tazemetostat, HMPL-689
Hutchmed
Relapsed/Refractory Lymphoma
05/26
12/26
NCT04908046: A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Completed
1
47
RoW
HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
Hutchmed
Advanced Malignant Solid Tumors
01/24
02/24
NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

Recruiting
1
10
RoW
TQH2929 Injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Generalized Pustular Psoriasis
02/25
02/25
NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Recruiting
1
81
RoW
HMPL-415S1
Hutchmed
Advanced Malignant Solid Tumors
05/25
06/26
ETRAS-China, NCT03080519: Endovascular Therapy for Renal Artery Stenosis in China

Not yet recruiting
N/A
5000
RoW
Endovascular Therapy
Chinese Academy of Medical Sciences, Fuwai Hospital
Renal Artery Obstruction, Hypertension, Renovascular
04/22
04/24
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events

Recruiting
N/A
100000
RoW
Chinese Academy of Medical Sciences, Fuwai Hospital
Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment
12/22
12/23
NCT06221722: Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation

Recruiting
N/A
150
RoW
BOLD-fMRI, Regular treatment of functional constipation, fluoxetine
Xijing Hospital of Digestive Diseases
Constipation - Functional, Refractory Constipation, Fluoxetine, fMRI, Brain Connectivity, Treatment Efficacy, Somatic Symptom, Mental Symptom
09/25
09/26
CNAVS, NCT06192238: China National Study of Adrenal Venous Sampling

Not yet recruiting
N/A
1500
RoW
adrenal venous sampling
Chinese Academy of Medical Sciences, Fuwai Hospital
Hyperaldosteronism
12/26
12/26
NCT06382896: Effect of Oliceridine on Rebound Pain

Recruiting
N/A
320
RoW
No intervention
The First Affiliated Hospital of Xiamen University
Rebound Pain, Arthroscopic Knee Surgery, Oliceridine
12/25
12/25
NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis

Recruiting
N/A
188
RoW
Ton-bridge carotid stent, WALLSTENT carotid stent
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Carotid Artery Stenosis
11/24
10/25
FLAVOUR II, NCT04397211: Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease

Active, not recruiting
N/A
1872
RoW
Angiography-derived FFR, IVUS
Second Affiliated Hospital, School of Medicine, Zhejiang University, Seoul National University Hospital, Affiliated Hangzhou First People's Hospital, Wuhan University, Peking University Third Hospital, The Affiliated Hospital of Hangzhou Normal University, RenJi Hospital, Second Hospital of Shanxi Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Changxing People's Hospital, The Affiliated Hospital of Medical College, Ningbo University, Jinhua Central Hospital, Shandong University of Traditional Chinese Medicine, Dongyang People's Hospital, The First Affiliated Hospital of Nanchang University, Jining First People's Hospital, Second Affiliated Hospital of Shantou University Medical College, Ulsan University Hospital, Huizhou Municipal Central Hospital, Zhejiang Greentown Cardiovascular Hospital, The Fourth People's Hospital of Jinan, First Affiliated Hospital of Kunming Medical University
Coronary Artery Disease
09/24
09/28
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
NCT05410652: Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)

Completed
N/A
1176
RoW
Detection of fecal samples with diagnostic kit, Sanger Sequencing group, Bacterial culture and drug sensitivity test of gastric mucosa samples
Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection, Helicobacter Pylori gyrA Levofloxacin Resistance Mutation, Fecal Drug Resistance Gene Detection, Helicobacter Pylori Infection, Susceptibility to
09/23
10/23

Download Options